News & Updates

Show Multimedia Only

Nasal microbiome predicts bronchopulmonary dysplasia in preterm infants

19 May 2022

In infants born preterm, the nasal microbiome seems to correlate with the incidence and severity of bronchopulmonary dysplasia, reports a recent study.

Nasal microbiome predicts bronchopulmonary dysplasia in preterm infants

19 May 2022

COVID boosters: Where from here?

19 May 2022 by

Having a fourth dose of COVID-19 vaccine (ie, second booster dose) substantially protects against severe illness in face of the Omicron variant, compared with only three doses of vaccine that were given more than 4 months earlier, according to data from the Israeli Ministry of Health database.

COVID boosters: Where from here?

19 May 2022

No apparent link between COVID-19 vax and cerebrovascular outcomes

13 May 2022 by

Several studies presented at AAN 2022 have revealed a lack of association between COVID-19 vaccination and negative cerebrovascular outcomes.

No apparent link between COVID-19 vax and cerebrovascular outcomes

13 May 2022

Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC

13 May 2022 by

Long-term findings from the pooled phase I/II CodeBreak 100 trial support the efficacy of sotorasib in certain patients with KRAS G12C–mutant non–small cell lung cancer (NSCLC).

Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC

13 May 2022

AZD7442 effectively TACKLEs COVID-19

12 May 2022 by

The phase III TACKLE trial highlights a new player in the COVID-19 treatment field – AZD7442 (tixagevimab/cilgavimab) – which demonstrated favourable efficacy and safety for nonhospitalized individuals with mild to moderate symptoms of the disease.

AZD7442 effectively TACKLEs COVID-19

12 May 2022

Remdesivir benefit greatest when given early in COVID-19

11 May 2022 by

Treatment with remdesivir is associated with reduced risk of hospitalization and death in non-hospitalized and hospitalized COVID-19 patients, respectively, especially when given early during the disease course, according to studies presented at ECCMID 2022.

Remdesivir benefit greatest when given early in COVID-19

11 May 2022

Adding canakinumab to SoC confers no survival benefit in advanced NSCLC

10 May 2022 by

The addition of the monoclonal anti-interleukin-1β antibody canakinumab to the standard of care (SoC) regimen of platinum doublet chemotherapy and pembrolizumab in the first-line setting did not improve progression-free survival (PFS) or overall survival (OS) in patients with advanced non-small-cell lung cancer (NSCLC), results of the phase III CANOPY-1 trial showed.

Adding canakinumab to SoC confers no survival benefit in advanced NSCLC

10 May 2022

Toripalimab plus chemo improves survival in NSCLC

09 May 2022 by

The addition of toripalimab to first-line chemotherapy led to significantly improved progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) without EGFR/ALK mutations, according to the updated results of the CHOICE-01* trial presented at the ASCO Plenary 2022.

Toripalimab plus chemo improves survival in NSCLC

09 May 2022

First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC

06 May 2022 by

Treatment comprising camrelizumab, carboplatin, and paclitaxel in the first-line setting improved overall survival (OS) in patients with advanced squamous non-small-cell lung cancer (NSCLC), according to updated results of the phase III CameL-sq trial from China.

First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC

06 May 2022

Adding durvalumab upfront to chemo ups long-term survival in SCLC

05 May 2022 by

Patients were threefold more likely to survive long term (beyond 3 years) when durvalumab was added to first-line chemotherapy, with or without tremelimumab, compared with those on chemotherapy alone, according to a post hoc analysis of long-term survivors (LTS) with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study.

Adding durvalumab upfront to chemo ups long-term survival in SCLC

05 May 2022

News & Updates

Filter by Specialty:

Specialty:

Nasal microbiome predicts bronchopulmonary dysplasia in preterm infants

Nasal microbiome predicts bronchopulmonary dysplasia in preterm infants

COVID boosters: Where from here?

COVID boosters: Where from here?

No apparent link between COVID-19 vax and cerebrovascular outcomes

No apparent link between COVID-19 vax and cerebrovascular outcomes

Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC

Sotorasib continues to impress at 2 years in KRAS G12C–mutant NSCLC

AZD7442 effectively TACKLEs COVID-19

AZD7442 effectively TACKLEs COVID-19

Remdesivir benefit greatest when given early in COVID-19

Remdesivir benefit greatest when given early in COVID-19

Adding canakinumab to SoC confers no survival benefit in advanced NSCLC

Adding canakinumab to SoC confers no survival benefit in advanced NSCLC

Toripalimab plus chemo improves survival in NSCLC

Toripalimab plus chemo improves survival in NSCLC

First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC

First-line camrelizumab-chemo combo boosts OS in advanced squamous NSCLC

Adding durvalumab upfront to chemo ups long-term survival in SCLC

Adding durvalumab upfront to chemo ups long-term survival in SCLC